TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +12.0% ·
share flow -1.4% ·
net new positions +10.7%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 875.63K | $561.43M | n/a | −3 |
| Q2 2026 | 189 | +3 | 258.75M | $130.52B | +5 | −3 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | n/a |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | n/a |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | n/a | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | n/a |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | n/a | −2 |
| Q2 2024 | 23 | n/a | 44.78M | $24.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 33.79M | n/a | $13.70B | 0.2% | n/c | 1 | SEC ↗ ×7 |
| 2 | BlackRock ✦ (passive) | 27.33M | n/a | $11.08B | 0.2% | n/c | 1 | SEC ↗ ×22 |
| 3 | State Street Global Advisors ✦ (passive) | 16.48M | -0.3% | $6.69B | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 4 | Capital World Investors ✦ | 9.58M | -13.4% | $3.88B | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 8.11M | -0.1% | $3.27B | 0.2% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 5.59M | -9.7% | $2.26B | 0.3% | ▼ Trim | 5 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 5.56M | -40.3% | $2.25B | 0.3% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 3.99M | n/a | $1.62B | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 9 | Fisher Asset Management ✦ | 2.69M | -0.9% | $1.09B | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 10 | PRIMECAP Management ✦ | 2.41M | +3.8% | $975.61M | 0.8% | ▲ Add | 5 | SEC ↗ |
| 11 | Wellington Management ✦ | 1.43M | -10.4% | $579.51M | 0.1% | ▼ Trim | 5 | SEC ↗ ×5 |
| 12 | D. E. Shaw & Co. ✦ | 1.33M | +463.4% | $537.63M | 0.6% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Arrowstreet Capital ✦ | 1.21M | +84.6% | $490.99M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 1.10M | +809.7% | $444.72M | 0.4% | ▲ Add | 5 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 637.12K | +92.3% | $258.33M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 16 | Baillie Gifford ✦ | 504.68K | -0.9% | $204.63M | 0.2% | ▼ Trim | 5 | SEC ↗ ×4 |
| 17 | Renaissance Technologies ✦ | 458.95K | +195.6% | $186.09M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 18 | Marshall Wace ✦ | 371.63K | New | $150.68M | 0.2% | New | 1 | SEC ↗ ×2 |
| 19 | Point72 Asset Management ✦ | 371.34K | +857.1% | $150.56M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 325.72K | +39.5% | $132.07M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 21 | Millennium Management ✦ | 311.00K | +65.0% | $126.10M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 108.69K | -48.1% | $44.07M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 23 | Glenview Capital ✦ | 100.00K | New | $40.55M | 1.2% | New | 1 | SEC ↗ |
| 24 | Gotham Asset Management ✦ | 79.76K | +108.0% | $32.34M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 25 | Markel Group ✦ | 49.55K | +10.1% | $20.09M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 26 | Dodge & Cox ✦ | 25.94K | -0.6% | $10.52M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 27 | Duquesne Family Office ✦ | 12.20K | New | $4.95M | 0.1% | New | 1 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 5.29K | +35.0% | $2.14M | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $150.68M | 0.2% |
| Glenview Capital | $40.55M | 1.2% |
| Duquesne Family Office | $4.95M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $11,944 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.73K sh · $2.29M
Officer · 400 sh · $245,752
Officer, Director · 62 sh · $38,982
Officer, Director · 33 sh · $20,677
Officer, Director · 101 sh · $63,166
Officer, Director · 79 sh · $49,613
Officer, Director · 2.15K sh · $1.35M
Officer, Director · 1.79K sh · $1.12M
Officer, Director · 3.01K sh · $1.89M
Officer, Director · 2.73K sh · $1.71M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology